IsoSciences Key Management Team
Rich Tyburski, President
As President of IsoSciences since July 2016, Rich oversees IsoSciences R&D, Operations, Custom Synthesis, and the development and production of over 1,000 novel catalog offerings for the clinical diagnostics and pharmaceutical markets. Rich has worked with diagnostic, nutritional, pharmaceutical and government laboratories around the world to produce the highest quality internal standards available.
He leads IsoSciences as a key manufacture for stable isotope labeled materials in the rapidly expanding market utilizing LC-MS/MS analysis. IsoSciences fulfills the market need for stable isotope labeled analytes, advanced intermediates, final drug substances and metabolites. IsoSciences has ensured customer requirements are met by using advanced processes and stringent quality specifications. Rich has experience in custom synthesis, analysis and ISO9001 Quality System implementation. Prior to his role as President, he was Vice President of Business Development, demonstrating success in expanding IsoSciences core business of new product development.
Prior to joining IsoSciences in 2007, Rich worked at Quest Pharmaceutical Services as a Staff Scientist specializing in LC-MS/MS GLP bio-equivalency studies. Rich obtained his bachelor’s degree in chemistry from Villanova University.
Stephen Jones, Chief Scientific Officer
Steve has a PhD in organic chemistry with almost 20 years of pharmaceutical and contract research experience. He currently serves as Chief Science Officer at IsoSciences, having primary technical responsibility for both custom research projects and catalog product development.
Since joining IsoSciences in 2005, Steve has provided custom synthesized compounds for customers ranging from Fortune 500 pharmaceutical companies to small research universities. These compounds are typically stable isotope labeled APIs and analytes for use in LC-MS/MS quantification. Steve has designed isotopically labeled steroids and vitamins that had never been previously available by utilizing the team’s vast knowledge obtained by years of custom synthesis.
He obtained his bachelor’s degree in chemistry from the University of Scranton, and his PhD from Villanova University where he synthesized the natural product Squalamine and analogs which were first isolated from the dogfish shark. Prior to IsoSciences, Steve has served in the positions of Associate Director of Medicinal Chemistry at Genaera Corporation and Director of Chemistry at Advanced Synthesis Group.
Carrington Smith, CEO
Carrington has over 20 years of experience in the industrial and chemical sectors providing business leadership, management, technology and commercialization solutions in a range of roles spanning technology management, business development, M&A analysis and execution, venture capital, open innovation, intellectual asset management and IP licensing. Carrington joined MPD Chemicals, parent company of IsoSciences, in February of 2014, as CEO. Prior to MPD Chemicals, Carrington held various leadership and managerial roles at Air Products and Chemicals, Inc. for over 20 years, creating value for advanced technologies, business case construction, valuations, contract negotiation, building company relationships, and making the complex simple. He also directed initiatives with start-ups and other large companies to generate collaborative relationships and generate business growth.
Carrington began his industrial career with Air Products and Chemicals, Inc. in a research and development role, having earned his BS in Chemistry from Virginia Commonwealth University and a Ph.D. in Chemistry with a focus on polymer science from Virginia Tech. Polymer development for gas separation membranes, electronic materials, adhesives and coatings were all part of Carrington’s early research and product development career at Air Products. He enjoys working with customers and partners to identify win-win relationships built on credibility, transparency and trust by leveraging the capabilities of MPD Chemicals, at the highest level, to provide custom chemical synthesis solutions. “Our customers desire critical enabling materials development, often starting with laboratory procedures and scales. Customers prefer to work with partners like us, who are willing and able to provide a pathway to economics that works for their application and who can remain a consistent supplier from lab to large scale multi-metric ton production. We are proud to serve an excellent current set of large and small customers with a diverse array of custom chemical solutions, and are excited about our future customer prospects as well. We serve an important and differentiated role bridging contract research type projects to pilot and large scale manufacturing capabilities, all within the same organization. ”